BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19307732)

  • 1. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
    Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
    Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
    Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
    Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of dopamine D2 receptors in neuroendocrine tumours.
    Pawlikowski M; Pisarek H; Winczyk K
    Endokrynol Pol; 2011; 62(5):388-91. PubMed ID: 22069098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
    Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
    Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
    Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
    Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
    Righi L; Volante M; Tavaglione V; Billè A; Daniele L; Angusti T; Inzani F; Pelosi G; Rindi G; Papotti M
    Ann Oncol; 2010 Mar; 21(3):548-555. PubMed ID: 19759190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
    Schmid HA; Lambertini C; van Vugt HH; Barzaghi-Rinaudo P; Schäfer J; Hillenbrand R; Sailer AW; Kaufmann M; Nuciforo P
    Neuroendocrinology; 2012; 95(3):232-47. PubMed ID: 22156600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes.
    Pinato DJ; Tan TM; Toussi ST; Ramachandran R; Martin N; Meeran K; Ngo N; Dina R; Sharma R
    Br J Cancer; 2014 Jan; 110(1):115-22. PubMed ID: 24231952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study.
    Diakatou E; Kaltsas G; Tzivras M; Kanakis G; Papaliodi E; Kontogeorgos G
    Endocr Pathol; 2011 Mar; 22(1):24-30. PubMed ID: 21287294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
    Hankus J; Tomaszewska R
    Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast.
    Kontogeorgos G; Thodou E; Choreftaki T
    Pathol Res Pract; 2020 Sep; 216(9):153066. PubMed ID: 32825939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
    Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
    Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey.
    Neşe N; Kumbaraci BS; Baydar DE; Kiliçaslan I; Sari AA; Şen S; Gönül II; Kankaya D; Özlük Y; Ermete M; Özağari A; Bal N; Kiremitçi S; Yildiz K; Tuna B; Şen N; Yörükoğlu K
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):253-60. PubMed ID: 25906124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of somatostatin and dopamine D2 receptors in endocrine tumors.
    Gatto F; Hofland LJ
    Endocr Relat Cancer; 2011 Dec; 18(6):R233-51. PubMed ID: 22135243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
    Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.